CD8A and neoplasm: Notably, provision of low doses of STING agonists cGAMP and ADU-S100 (aka ML-RR-S2-CDA, MIW815) coordinately promote VN and CD8+ T cell-dependent control of tumor growth in murine models of breast carcinoma, lung carcinoma and melanoma (67, 68, 73).